MAINZ BIOMED NV (MYNZ) Stock Income Statement
NASDAQ:MYNZ - NL0015000LC2 - Common Stock
1.61 USD
-0.02 (-1.23%)
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 894.00K | 895.50K | 530.00K | 580.00K | 490.00K | |||
| Cost Of Goods | 320.00K | 390.00K | 350.00K | 400.00K | 370.00K | |||
| Gross Profit | 574.90K | 509.70K | 180.00K | 180.00K | 120.00K | |||
| Operating Expenses | 19.43M | 26.67M | 26.69M | 9.90M | 800.00K | |||
| Research and Development | 5.20M | 9.07M | 3.55M | 440.00K | 290.00K | |||
| Selling, General, and Administrative Expenses | 13.00M | 17.00M | 22.88M | 9.40M | 450.00K | |||
| Operating Income | -18.75M | -27.06M | -26.51M | -9.72M | -680.00K | |||
| Interest Income/Expense | -1.07M | -809.60K | -210.00K | -200.00K | -180.00K | |||
| Other Income/Expense | -1.92M | 1.10M | 330.00K | 250.00K | 260.00K | |||
| Non Recurring Items | -250.00K | 60.00K | 0.00 | -2.02M | 10.00K | |||
| Income Before Taxes | -22.00M | -26.00M | -26.39M | -11.69M | -590.00K | |||
| Net Income | -22.00M | -26.00M | -26.39M | -11.69M | -590.00K | |||
| EBITDA | -17.73M | -26.19M | -26.13M | -9.65M | -620.00K | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -22.72 | -64.02 | -74.56 | -33.49 | -1.74 | |||
| Non GAAP EPS | N/A | -48.05 | N/A | N/A | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 64.31% | 56.92% | 33.96% | 31.03% | 24.49% | |||
| Profit Margin | -2460.85% | -2903.41% | -4979.25% | -2015.52% | -120.41% | |||
| Operating Profit Margin | -2097.32% | -3021.78% | -5001.89% | -1675.86% | -138.78% | |||
All data in USD